Literature DB >> 8407281

Effect of mycophenolate mofetil (RS-61443) on cytokine production: inhibition of superantigen-induced cytokines.

S E Nagy1, J P Andersson, U G Andersson.   

Abstract

The effects of the immunosuppressant mycophenolate mofetil (MPAM, RS-61443) on cytokine production at the single cell level were assessed using in vitro activated human mononuclear cells. Cytokine production was studied with UV microscopy of fixed and permeabilized cells stained with cytokine specific monoclonal antibodies (mAbs). The cytokines evaluated included interleukin-1 alpha (IL-1 alpha), IL-1 beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-10 interferon gamma (IFN-gamma), tumor necrosis factor alpha (TNF-alpha), TNF-beta, and granulocyte macrophage-colony stimulating factor (GM-CSF). MPAM exhibited a marked antiproliferative effect without cytotoxicity in all mononuclear cell cultures. Six to 24 hours after stimulation with the superantigen Staphylococcus aureus enterotoxin A (SEA), most cytokine production was unaffected by MPAM at therapeutic concentrations (10(-6) M), with the exception of GM-CSF. In contrast, by 48 h after antigen activation, MPAM significantly inhibited all studied cytokine production (p < 0.05). Cyclosporin A (CsA), used as a control at a concentration of 100 ng/ml, inhibited production of all studied cytokines, at all time points. Monokine production after lipopolysaccharide (LPS) stimulation was unaffected by MPAM. Similarly, the production of most of the cytokines studied after mitogen stimulation with phorbol ester (PMA) plus calcium ionophore (ionomycin) was not affected by MPAM, in comparison to CsA which demonstrated significant inhibition of all cytokines tested under these conditions. However, a late inhibitory effect on IL-3 production was seen by MPAM at 48 h after mitogenic stimulation. Further observations are required to explain the divergent results on cytokine production by MPAM in superantigen-activated and mitogen-activated human mononuclear cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8407281     DOI: 10.1016/0162-3109(93)90062-u

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  8 in total

1.  Modulation of innate and antigen-specific immune functions directed against Listeria monocytogenes by fungal toxins in vitro.

Authors:  I Herter; G Geginat; H Hof; C Kupfahl
Journal:  Mycotoxin Res       Date:  2014-02-14       Impact factor: 3.833

Review 2.  Progress on the development of therapeutics against West Nile virus.

Authors:  Michael S Diamond
Journal:  Antiviral Res       Date:  2009-06-06       Impact factor: 5.970

Review 3.  The role of cytokines in the pathogenesis of Langerhans cell histiocytosis.

Authors:  G Kannourakis; A Abbas
Journal:  Br J Cancer Suppl       Date:  1994-09

Review 4.  Potential of immunosuppressive agents in cerebral ischaemia.

Authors:  Yogendra Kumar Gupta; Anjali Chauhan
Journal:  Indian J Med Res       Date:  2011-01       Impact factor: 2.375

5.  Acute Chelation Therapy-Associated Changes in Urine Gadolinium, Self-reported Flare Severity, and Serum Cytokines in Gadolinium Deposition Disease.

Authors:  Holden T Maecker; Janet C Siebert; Yael Rosenberg-Hasson; Lorrin M Koran; Miguel Ramalho; Richard C Semelka
Journal:  Invest Radiol       Date:  2021-06-01       Impact factor: 10.065

6.  Systemic immunosuppression and risk of age-related macular degeneration.

Authors:  Harpal S Sandhu; Joshua Lambert; Yan Xu; Henry J Kaplan
Journal:  PLoS One       Date:  2018-09-20       Impact factor: 3.240

7.  Role of serum interleukin-6 in deciding therapy for multidrug resistant oral lichen planus.

Authors:  Sinny Goel; Akanksha Marwah; Smita Kaushik; Vijay K Garg; Sunita Gupta
Journal:  J Clin Exp Dent       Date:  2015-10-01

8.  In-vitro influence of mycophenolate mofetil (MMF) and Ciclosporin A (CsA) on cytokine induced killer (CIK) cell immunotherapy.

Authors:  Melanie Bremm; Sabine Huenecke; Olga Zimmermann; Verena Pfirrmann; Andrea Quaiser; Halvard Bonig; Jan Soerensen; Thomas Klingebiel; Eva Rettinger; Peter Bader; Claudia Cappel
Journal:  J Transl Med       Date:  2016-09-13       Impact factor: 5.531

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.